(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Compass Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast CMPX's revenue for 2025 to be $4,541,818,535, with the lowest CMPX revenue forecast at $4,419,364,173, and the highest CMPX revenue forecast at $4,664,272,897. On average, 5 Wall Street analysts forecast CMPX's revenue for 2026 to be $17,412,459,947, with the lowest CMPX revenue forecast at $5,324,700,918, and the highest CMPX revenue forecast at $30,185,688,226.
In 2027, CMPX is forecast to generate $31,004,756,561 in revenue, with the lowest revenue forecast at $16,758,361,028 and the highest revenue forecast at $51,040,629,231.